FDA 483 OBSERVATION · #16 OF 1,923 MOST-CITED
Documentation
FDA cited this observation 900 times across 795 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this grouping is not
An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
Documentation required by the quality system was missing, incomplete, or inadequate — procedures, records, or specifications that should exist to define and evidence controlled activities were not there or did not say enough to control the work.
Why FDA writes it — In a regulated quality system, if it isn’t documented, it didn’t happen. Documentation is both the instruction (what to do) and the evidence (what was done); a gap in either means the activity cannot be shown to be controlled, which is why documentation is one of the most frequently cited areas across every program.
- Maintain the documentation the quality system requires — procedures, work instructions, specifications, and records — controlled and current.
- Write documents to actually control the activity: specific enough that the work is reproducible and the acceptance criteria are clear.
- Record activities contemporaneously and completely, with attribution.
- Control document versions and changes so people work to the current, approved document.
- Documents written to satisfy an auditor rather than to run and evidence the process.
- Version control gaps, so obsolete documents remain in use alongside current ones.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 0.9× the rate of the average FDA-cited firm (7.2% vs 7.8%), across 795 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
Corrective and preventive action activities and/or results have not been adequately documented.
Corrective and preventive action activities and/or results have not been adequately documented.
Corrective and preventive action activities and/or results have not been adequately documented.
Corrective and preventive action activities and/or results have not been documented.
Process validation activities have not been documented.
Corrective and preventive action activities and/or results have not been adequately documented.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →